Vaxart Q4 Earnings Call Highlights

Vaxart reported its Q4 earnings, highlighting significant advancements in their oral vaccine platform. The company is optimistic about upcoming clinical trials and potential partnerships that could enhance their market position. However, concerns were raised about competition in the vaccine space, which may impact investor sentiment. Vaxart's management provided guidance on revenue expectations for the upcoming quarter, indicating a cautious but hopeful outlook. Overall, the results showed potential for growth but also raised questions about market competition.